$256.00 – $575.00
Property Name | Property Value | Reference |
---|---|---|
Molecular Weight | 194.11 | Computed by PubChem 2.1 (PubChem release 2021.05.07) |
XLogP3-AA | 0.8 | Computed by XLogP3 3.0 (PubChem release 2021.05.07) |
Hydrogen Bond Donor Count | 1 | Computed by Cactvs 3.4.8.18 (PubChem release 2021.05.07) |
Hydrogen Bond Acceptor Count | 6 | Computed by Cactvs 3.4.8.18 (PubChem release 2021.05.07) |
Rotatable Bond Count | 2 | Computed by Cactvs 3.4.8.18 (PubChem release 2021.05.07) |
Exact Mass | 194.03031189 | Computed by PubChem 2.1 (PubChem release 2021.05.07) |
Monoisotopic Mass | 194.03031189 | Computed by PubChem 2.1 (PubChem release 2021.05.07) |
Topological Polar Surface Area | 55.1 Ų | Computed by Cactvs 3.4.8.18 (PubChem release 2021.05.07) |
Heavy Atom Count | 13 | Computed by PubChem |
Formal Charge | 0 | Computed by PubChem |
Complexity | 214 | Computed by Cactvs 3.4.8.18 (PubChem release 2021.05.07) |
Isotope Atom Count | 0 | Computed by PubChem |
Defined Atom Stereocenter Count | 0 | Computed by PubChem |
Undefined Atom Stereocenter Count | 0 | Computed by PubChem |
Defined Bond Stereocenter Count | 0 | Computed by PubChem |
Undefined Bond Stereocenter Count | 0 | Computed by PubChem |
Covalently-Bonded Unit Count | 1 | Computed by PubChem |
Compound Is Canonicalized | Yes | Computed by PubChem (release 2021.05.07) |
Room temperature free S&H from Ann Arbor, MI. Shipping on ice packs available upon request.
Storage stability not tested. Recommended storage at -20°C.
≥ 1 year
By: Jain, Rakesh K.; Low, Eddy; Francavilla, Charles; Shiau, Timothy P.; Kim, Bum; Nair, Satheesh K.
World Intellectual Property Organization, WO2010054009 A1 2010-05-14
The present application relates to N-chlorinated oxazolidinone, hydantoin and imidazolidinone compounds or pharmaceutically acceptable salts thereof, and associated compositions and methods of use as antimicrobial agents, including antibacterial, antiinfective, disinfectant, antifungal, germicidal and antiviral agents. 3-Chloro-4-methyl-4-(methylsulfonic acid)oxazolidin-2-one (Compound 22-01) was prepared and its antibacterial and antifungal activities were demonstrated in vitro.
By: Martinez Botella, Gabriel; Griffin, Andrew Mark
World Intellectual Property Organization, WO2021195066 A2 2021-09-30 |
The present invention is directed to, in part, compounds of formula I and compositions useful for preventing and/or treating a
neurol. disease or disorder, a disease or condition relating to excessive neuronal excitability, and/or a gain-of-function mutation in a
gene (e.g., KCNT1). Methods of treating a neurol. disease or disorder, a disease or condition relating to excessive neuronal excitab
ility, and/or a gain-of-function mutation in a gene such as K CNT1 are also provided herein.